The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - ADC Therapeutics; Cellerant Therapeutics; Incyte; Janssen Research & Development; MedImmune; Pharmacyclics; Puma Biotechnology (I); Verastem
Speakers' Bureau - AstraZeneca; Celgene; Genzyme
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Yuliya Linhares
No Relationships to Disclose
 
Mitul Gandhi
No Relationships to Disclose
 
Michael Chung
No Relationships to Disclose
 
Helena Adamis
Employment - ADC Therapeutics; Fresenius Kabi BioSimiliars
 
David Ungar
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
 
Carmelo Carlo-Stella
Honoraria - AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Incyte; Janssen Oncology; Merck Sharp & Dohme; Takeda
Consulting or Advisory Role - ADC Therapeutics; Celgene/Bristol-Myers Squibb; Incyte; Karyopharm Therapeutics; Roche; Sanofi
Research Funding - ADC Therapeutics (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - ADC Therapeutics; Janssen; Roche; Takeda